Rituximab: Uses in Dermatology.
Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.
School of Medicine.
K
K
Gleghorn
Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.
J
J
Wilson
Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.
M
M
Wilkerson
D003240:Connective Tissue Diseases / Q000188:drug therapy; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D056687:Off-Label Use; D010392:Pemphigus / Q000188:drug therapy; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy
D000069283:Rituximab